NYSE$LCTX
Lineage Cell Therapeutics In · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Lineage Cell Therapeutics reported Q3 2025 total revenues of $3.7M with a net loss of $29.8M.
Collaboration and royalty revenue totaled $3.7 million while OpRegen and platform programs advanced. Net loss was $29.8 million as R&D and manufacturing scale-up continued.
- Q3 total revenues $3.7M.
- Net loss $29.8M.
- Roche collaboration revenue recognized over time.
- Cell therapy manufacturing and clinical milestones ahead.
Headline financials
Revenue & EPS history
Lineage · Revenue · Quarterly
$3.68M
Revenue by segment
Lineage · $700K total across 1 segment · Q4 2019
- Royalties and licensing$700K—100.0%
Forward guidance
The filing discusses Lineage Cell Therapeutics's outlook, capital priorities, and key risks, including guidance or operating targets where disclosed.
Tailwinds
- Lineage Cell Therapeutics cites execution and demand supporting the near-term outlook.
- Balance sheet and capital allocation remain focal points in the filing.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competition, and input costs may pressure margins quarter to quarter.
- One-time items and segment mix can affect comparability versus prior periods.
- Clinical and regulatory timelines drive funding needs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+0.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.6%
Avg return
30 days after
50%
31 / 62 earnings
Positive
+16.6%
Q4 2016
Best reaction
-14.5%
Q1 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.5% | -4.6% | -2.3% | |
| Q4 2025 | +0.5% | -8.7% | -14.7% | |
| Q3 2025 | +1.2% | +11.6% | -0.6% | |
| Q1 2025 | -0.1% | +6.4% | +72.3% | |
| Q4 2024 | +0.4% | -1.9% | -22.6% | |
| Q3 2024 | -5.3% | -1.1% | -44.0% | |
| Q2 2024 | +4.4% | -4.6% | -3.4% | |
| Q1 2024 | +0.9% | -10.3% | -16.4% | |
| Q4 2023 | +15.0% | +9.7% | +23.9% | |
| Q3 2023 | -5.5% | -8.2% | -5.5% | |
| Q2 2023 | +0.0% | +1.4% | -5.6% | |
| Q1 2023 | -3.5% | -4.9% | -3.5% | |
| Q4 2022 | -2.1% | -4.8% | -6.2% | |
| Q3 2022 | +15.2% | +4.8% | -2.4% | |
| Q2 2022 | +0.6% | -3.2% | -16.7% | |
| Q1 2022 | -5.9% | +1.7% | +17.6% | |
| Q4 2021 | -5.6% | -14.8% | -3.5% | |
| Q3 2021 | -0.4% | +0.4% | -19.0% | |
| Q2 2021 | -1.1% | -7.9% | -12.1% | |
| Q1 2021 | -0.4% | +0.9% | +26.4% | |
| Q4 2020 | +10.2% | +21.0% | +32.3% | |
| Q3 2020 | +7.4% | +7.4% | +32.0% | |
| Q2 2020 | +3.7% | +2.3% | -2.3% | |
| Q1 2020 | -3.7% | -11.5% | -7.3% | |
| Q4 2019 | -5.3% | -12.7% | -2.5% | |
| Q3 2019 | +6.6% | +19.2% | -5.5% | |
| Q2 2019 | -8.9% | -8.9% | -8.9% | |
| Q1 2019 | +0.8% | -10.8% | -16.7% | |
| Q4 2018 | +10.2% | +0.0% | -17.8% | |
| Q3 2018 | -8.6% | -17.1% | -27.1% | |
| Q2 2018 | -3.7% | -4.6% | +14.1% | |
| Q1 2018 | +0.9% | +2.3% | +3.7% | |
| Q4 2017 | +0.7% | -4.3% | -10.1% | |
| Q3 2017 | +14.3% | +6.3% | +8.5% | |
| Q2 2017 | +6.4% | +6.0% | +8.3% | |
| Q1 2017 | +0.3% | +1.9% | +1.6% | |
| Q4 2016 | +16.6% | +5.5% | +5.8% | |
| Q3 2016 | +0.3% | +0.3% | +1.3% | |
| Q2 2016 | -5.4% | -6.0% | +5.1% | |
| Q1 2016 | -4.6% | — | — | |
| Q4 2015 | +9.5% | — | — | |
| Q3 2015 | -7.6% | — | — | |
| Q2 2015 | -6.2% | — | — | |
| Q4 2014 | +1.2% | — | — | |
| Q3 2014 | +0.3% | — | — | |
| Q1 2014 | +6.4% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q3 2013 | -1.8% | — | — | |
| Q2 2013 | +0.5% | — | — | |
| Q1 2013 | +8.5% | — | — | |
| Q4 2012 | -9.5% | — | — | |
| Q3 2012 | -4.5% | — | — | |
| Q2 2012 | -4.3% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -7.1% | — | — | |
| Q2 2011 | +3.0% | — | — | |
| Q1 2011 | -2.9% | — | — | |
| Q4 2010 | -4.7% | — | — | |
| Q3 2010 | +6.9% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q1 2010 | -14.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro